Provider Networks & CINs
Expert articles and analysis related to provider networks & cins.
AI Summary â Last 24 Hours
CMSâs IPAY 2029 Medicare Drug Price Negotiation proposed rule is drawing detailed policy feedback from Brookings and Duke-Margolis, while Tevaâs partially revived IRA litigation signals continuing uncertainty around negotiated drug pricing that will flow through Part D affordability, specialty-drug management, and total-cost-of-care benchmarks for ACOs and CINs. For provider networks, the immediate implication is contract and pharmacy-risk planning: lower negotiated prices may reduce patient cost barriers and downstream avoidable utilization, but litigation and rulemaking uncertainty complicate actuarial assumptions for Medicare Advantage, ACO REACH, MSSP, and Medicaid managed care populations. See [Brookings on the IPAY 2029 rule](https://news.google.com/rss/articles/CBMiuwFBVV95cUxOamtaQ2kxTlc1NTQ4ZkVaa2l5LUNBbHBwRzF6TmlZRVppbERrYmw2T25aMmtpWTZSTkg4X05JYVFIc1FMUzZVanFmcGhvOVBFdVRjMDAwM2ZxLUFLMlJiT0ZTcFU5dVBVQW5ZU0RFS054UWJ4bktmcFhzZGVRTjhySGhLeUppY0hvYk0zQmdtdG1aWWNfamo2YWFZV2xyUU
Related Articles
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
After a lower court rejected Teva's case last fall, a federal appeals court has revived part of the drugmakerâs lawsuit against Medicare negotiations. The DC Circuit Court ruled on Tuesday that Teva...
Response to Senate Finance Committee request for information on policies for lowering drug prices
Response to Senate Finance Committee request for information on policies for lowering drug prices  Brookings
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029Â Â Brookings
Legislative Proposals Aim to Modify the 340B Program
STAT+: The White House declares âpromises made, promises keptâ on lowering drug prices. Nice try
In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative that doesn't reflect the full story.
Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting
List prices for brand-name drugs have declined significantly in 2026. But the reasons behind it may have more to do with a Biden-era law than any of the Trump administration's recent initiatives, expe...
Where Does Your Prescription Drug Dollar Go?
Where Does Your Prescription Drug Dollar Go?  AHIP
Comment Letter on CMS IPAY 2029 Proposed Rule
Comment Letter on CMS IPAY 2029 Proposed Rule  Margolis Institute for Health Policy
Universal Coverage Might Be Nice, but an AI Tax Is Necessary
By KIM BELLARD I was amused â oh, I should be polite and say âinterestedâ â to see a new study, led by researchers from Yale School of Public Medicine, about theContinue reading...
STAT+: Government workers feel the squeeze on health care
Municipalities are struggling with the cost of health insurance for their workers, and states are facing a major decision on Medicaid drug coverage.